• 1
    Singh VV, Toskes PP. Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Treat Options Gastroenterol 2004; 7: 1928.
  • 2
    Kerlin P, Wong L. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology 1988; 95: 9828.
  • 3
    Kerlin P. Glucose-H2 breath test for small intestinal bacterial overgrowth. Gastroenterology 1990; 98: 2534.
  • 4
    Corazza GR, Menozzi MG, Strocchi A, et al. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology 1990; 98: 3029.
  • 5
    Hoover W, Gerlach E, Hoban D, et al. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 1993; 16: 1118.
  • 6
    Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995; 49: 46784.
  • 7
    Descombe J, Dubourg D, Picard M, et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994; 14: 516.
  • 8
    Williams R, James OF, Warnes TW, et al. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000; 12: 2038.
  • 9
    Di Stefano M, Malservisi S, Veneto G, et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000; 14: 5516.
  • 10
    Attar A, Flourie B, Rambaud JC, et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999; 117: 7947.
  • 11
    Castiglione F, Rispo A, Di Girolamo E, et al. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 110712.
  • 12
    Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 4129.
  • 13
    Hazenberg MP, Pennock-Schroder AM, van de Merwe JP. Reversible binding of polymyxin B and neomycin to the solid part of faeces. J Antimicrob Chemother 1986; 17: 3339.
  • 14
    Miglioli PA, Allerberger F, Calabro GB, et al. Effects of daily oral administration of rifaximin and neomycin on faecal aerobic flora in rats. Pharmacol Res 2001; 44: 3735.
  • 15
    Corazza GR, Ventrucci M, Strocchi A, et al. Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin. J Int Med Res 1988; 16: 3126.